Recruiting
Breast cancer+1
RecruitingStudy of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment
Registered drugNo placebo
Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment
Registered drugNo placebo
- Disease:Breast cancerTriple negative breast cancer
- Substances:CapecitabineCarboplatin+5
Countries:
Romania
Romania- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:Bristol-Myers Squibb Services Unlimited Company
